What are the main indications for bimekizumab?

Bimekizumab is a biological agent with the core mechanism of inhibiting IL-17A and IL-17F. Its indications focus on immune-mediated inflammatory diseases. The main indication approved overseas is moderate to severe plaque psoriasis, which is suitable for adult patients who require systemic treatment or phototherapy. Since psoriasis is a chronic, relapsing skin disease that is closely related to the immune system, IL-17A and IL-17F in the inflammatory pathway are regarded as key driving factors. Therefore, by blocking these two targets at the same time, bichizumab can more effectively inhibit the skin inflammatory response, reduce excessive epidermal hyperplasia, and control skin lesions faster and more comprehensively.

In addition to plaque psoriasis, bicizumab is also approved in several countries for psoriatic arthritis (PsA). Psoriatic arthritis often affects joints, tendon sheaths and entheseal tissues at the same time, and is accompanied by varying degrees of skin symptoms. Since its inflammatory mechanism is highly overlapping with that of psoriasis, and the IL-17 pathway plays an equally significant role in disease activity, the strategy of dual blocking IL-17A and 17F can work at both the skin and joint levels to provide patients with more systemic relief.

In some countries and regions, bichizumab is also used to treat immune diseases mainly characterized by spinal inflammation, such as axial spondyloarthritis (including ankylosing spondylitis). In this type of disease, the IL-17 signaling pathway also plays an important role. Therefore, the drug's dual-target mechanism can reduce spinal ulcerative inflammation, improve stiffness and limited activity, thereby helping patients improve motor function and long-term quality of life.

In addition, hidradenitis suppurativa (HS) is one of the potential indications for bicizumab that has attracted much attention in recent years. The main influencing factors of this disease are recurrent painful subcutaneous nodules, fistula formation and chronic skin ulceration. Due to current limited treatment options, the role of the IL-17 pathway in disease has been increasingly valued, and the clinical development progress of bichizumab is also accelerating.

Reference materials:https://www.drugs.com/bimekizumab.html